Comparative Pharmacology
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFAZOLIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF IN PLASTIC CONTAINER versus CEFAZOLIN SODIUM.
ANCEF IN PLASTIC CONTAINER vs CEFAZOLIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and autolytic enzyme inhibition.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, PBP3, and PBP4, thereby preventing cross-linking of peptidoglycan chains. This leads to cell lysis and death.
1-2 g IV/IM every 8 hours. Maximum 12 g/day.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 10-30 hours in ESRD (CrCl <10 mL/min); anephric patients up to 40 hours.
Approximately 1.8 hours (range 1.2-2.2 h) in normal renal function; prolonged in renal impairment (up to 30-40 h in ESRD)
Primarily renal (80-96% unchanged within 24 hours via glomerular filtration and tubular secretion); minimal biliary (<1%) and fecal (<1%).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); minimal biliary (1-2%); fecal (<1%)
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic